ORIC Pharmaceuticals Announces $85 Million Private Placement Financing Portfolio News / By Karina Tin June 26, 2023 ORIC Pharmaceuticals Announces $85 Million Private Placement Financing Read More »
Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 83rd American Diabetes Association Scientific Sessions Portfolio News / By Karina Tin June 23, 2023 Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 83rd American Diabetes Association Scientific Sessions Read More »
Escient Pharmaceuticals Announces Positive Results From Phase 1 Study of EP262, A First-In-Class Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders Portfolio News / By Karina Tin June 20, 2023 Escient Pharmaceuticals Announces Positive Results From Phase 1 Study of EP262, A First-In-Class Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders Read More »
Neurona Therapeutics Presents One-Year Data on the First Patient Treated with NRTX-1001 Cell Therapy in an Ongoing Phase I/II Trial for Drug-resistant Focal Epilepsy Portfolio News / By Karina Tin June 15, 2023 Neurona Therapeutics Presents One-Year Data on the First Patient Treated with NRTX-1001 Cell Therapy in an Ongoing Phase I/II Trial for Drug-resistant Focal Epilepsy Read More »
Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications Portfolio News / By Karina Tin June 14, 2023 Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications Read More »
Effector Therapeutics Raises a Total of $16.2M in Gross Proceeds From Two Recent Registered Direct Offerings Portfolio News / By Karina Tin June 9, 2023 Effector Therapeutics Raises a Total of $16.2M in Gross Proceeds From Two Recent Registered Direct Offerings Read More »
Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke Portfolio News / By Karina Tin June 5, 2023 Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke Read More »
Eikon Therapeutics Acquires Global Rights to Clinical-Stage Assets and Announces Emerging Drug Development Pipeline Portfolio News / By Karina Tin June 01, 2023 Eikon Therapeutics Acquires Global Rights to Clinical-Stage Assets and Announces Emerging Drug Development Pipeline Read More »
